Pharmachronicles

Top Menu

  • Home
  • Our Blog
  • Contact Us

Main Menu

  • Home Page
  • STUDENTS ZONE
  • Syllabus
  • Seminars & conferences
  • Online classes
    • Register
Sign in / Join

Login

Welcome! Login in to your account
Lost your password?

Lost Password

Back to login
  • Home
  • Our Blog
  • Contact Us

Pharmachronicles

Header Banner

Pharmachronicles

  • Home Page
  • STUDENTS ZONE
  • Syllabus
  • Seminars & conferences
  • Online classes
    • Register
  • UGC-Cancelled-List of journals

  • NAAC stops accepting applications for accreditation from pharmacy colleges

  • Pursuing MPhil/PhD while working as a teacher will effect experience: UGC

  • Public notice by government of india ministry of health and family welfare

FDA Alerts
Home›FDA Alerts›FDA Approves Humanized Monoclonal Antibody For Migraine Treatment.

FDA Approves Humanized Monoclonal Antibody For Migraine Treatment.

By Sriram Nagarajan
September 30, 2018
781
0
Share:

Eli Lilly and Company has announced that the U.S. Food and Drug Administration (FDA) has approved Emgality™ (galcanezumab-gnlm) 120 mg injection for the preventive treatment of migraine in adults at 27 September of this month.

Migraine is a disabling, neurological disease characterized by recurrent episodes of severe headache accompanied by other symptoms including nausea, vomiting, sensitivity to light and sound, and changes in vision.

Emgality is a humanized monoclonal antibody that binds to calcitonin gene-related peptide (CGRP) and blocks its binding to the receptor. Emgality offers a once-monthly, self-administered, subcutaneous injection.

“Despite the devastating impact of migraine, only about 10 percent of people living with the disease are currently taking a preventive treatment,” said Christi Shaw, president, Lilly Bio-Medicines. “For more than two decades, Lilly has recognized this unmet need, and we have worked tirelessly to develop a new option specifically designed for the prevention of migraine. With this approval, we are thrilled to offer a preventive treatment option to adults living with this disease.”

The efficacy and safety of Emgality was demonstrated in two Phase 3 clinical trials in patients with episodic migraine (EVOLVE-1 and EVOLVE-2) and one Phase 3 clinical trial in patients with chronic migraine (REGAIN).

The recommended dose for Emgality is 240 mg (two consecutive subcutaneous injections of 120 mg each) once as a loading dose, followed by monthly doses of 120 mg injected subcutaneously.1

Indications and Usage

Emgality is a calcitonin gene-related peptide (CGRP) antagonist indicated for the preventive treatment of migraine in adults.

Important Safety Information

Contraindications

Emgality is contraindicated in patients with serious hypersensitivity to galcanezumab-gnlm or to any of the excipients.

Warnings and Precautions

Hypersensitivity Reactions
Hypersensitivity reactions (e.g., rash, urticaria and dyspnea) have been reported with Emgality in clinical studies. If a serious or severe hypersensitivity reaction occurs, discontinue administration of Emgality and initiate appropriate therapy. Hypersensitivity reactions can occur days after administration and may be prolonged.

Adverse Reactions
The most common adverse reactions (incidence ≥2% and at least 2% greater than placebo) in Emgality clinical studies were injection site reactions.

SOURCE: Eli Lilly and Company.

TagsCGRPEli Lilly and companyfda
Previous Article

Positive vibes for HPV vaccination study.

Next Article

Pioneers in the medical field awarded with ...

0
Shares
  • 0
  • +
  • 0
  • 0
  • 0
  • 0

Sriram Nagarajan

Related articles More from author

  • BLOGS

    FDA approves pill with sensor

    November 15, 2017
    By admin
  • Uncategorized

    FDA approve new robotically-assisted surgical device for adult patients

    October 21, 2017
    By admin
  • FDA Alerts

    FDA approves a new drug to treat malaria which could help millions.

    July 24, 2018
    By Sriram Nagarajan
  • FDA AlertsMedical & HealthMedical research

    FDA approves a new clinical trial for non-healing wounds.

    October 28, 2017
    By admin
  • BLOGS

    FDA is carefully evaluating prescription opioid medications approved to treat cough in children

    July 16, 2015
    By admin
  • BLOGS

    Treating Hereditary blindness by gene therapy will be a revolution in medical field

    October 20, 2017
    By admin

Leave a reply Cancel reply

You may interested

  • Phama news

    DRUG INDUCED PULMONARY DISEASE

  • BLOGS

    Is Vitamin B17 Safe For Anticancer Treatment

  • Medical & Health

    Clinical trial of the HIV vaccine proves safe in human use.

  • LATEST REVIEWS

  • TOP REVIEWS

  • Dispelling Myths About Generic Medications: Unveiling their Safety, Effectiveness, and Cost-Saving advantages

  • Pharmacists are not eligible for certificate program of community health

    0
  • A New Class of Antimicrobials Has Just Been Found in Human Breast Milk Fresh super ...

    0

Timeline

  • August 3, 2023

    List of UGC declared 20 universities as fake, not authorised to award degrees.

  • July 28, 2023

    Dispelling Myths About Generic Medications: Unveiling their Safety, Effectiveness, and Cost-Saving advantages

  • May 24, 2021

    LIST OF SCOPUS INDEXED JOURNALS APRIL 2021

  • October 20, 2020

    List of UGC Approved journals 2020

  • June 8, 2020

    Brain Tumor Day -8th June – Endoscopic surgery: An innovative approach to treat brain tumour

Latest Comments

  • Sowmya V
    on
    December 13, 2019
    Nice keep it up

    Blood Test Might Predict Pregnancy Due Date and Preterm Birth

Find us on Facebook

Follow Us on Instagram

logo

Dui viverra Faucibus aliquet quis phasellus accumsan. Donec et facilisis sociosqu sed tortor elit eu aliquid turpis ridiculus.

Fly, shall, have greater fifth spirit midst under from stars thing is, had creepeth multiply kind. Man may they’re meat years have third bring replenish air two light deep fill.

About us

  • Dr.N.Sriram, Founder CEO, Pharmachronicles, HITS college of Pharmacy, Ghatkesar, Hyderabad, India
  • 9704361947
  • pharmachronicles@gmail.com
  • Recent

  • Popular

  • Comments

  • List of UGC declared 20 universities as fake, not authorised to award degrees.

    By mythandintegrity
    August 3, 2023
  • Dispelling Myths About Generic Medications: Unveiling their Safety, Effectiveness, and Cost-Saving advantages

    By mythandintegrity
    July 28, 2023
  • LIST OF SCOPUS INDEXED JOURNALS APRIL 2021

    By admin
    May 24, 2021
  • List of UGC Approved journals 2020

    By admin
    October 20, 2020
  • Blood Test Might Predict Pregnancy Due Date and Preterm Birth

    By Sundari srinidhi
    December 12, 2019
  • FDA is carefully evaluating prescription opioid medications approved to treat cough in children

    By admin
    July 16, 2015
  • Record Numbers of FDA‑Approved Drugs: Recent Trends

    By admin
    July 16, 2015
  • There make for Sixth that multiply blessed two divide creeping

    By admin
    July 16, 2015
  • Sowmya V
    on
    December 13, 2019

    Blood Test Might Predict Pregnancy Due Date and Preterm Birth

    Nice keep it up

Photostream

    Follow us

    • Contact
    • STUDENTS ZONE
    • About Us
    © Copyright Pharmachronicles. All rights reserved.